Navigation Links
Second Trial in the Largest Hepatitis C Outbreak in U.S. Begins - Mainor Eglet Law Firm Files for Plaintiffs
Date:8/5/2011

LAS VEGAS, Aug. 5, 2011 /PRNewswire/ -- Jury selection in the second trial in the largest hepatitis C outbreak in U.S. history has begun in Clark County, Nevada. The Nevada Supreme Court lifted the stay allowing the case to go to trial when it was determined by the court that nurse David Hambrick, a witness for the defense Teva Inc. and Baxter Inc., "does not possess the requisite skill, knowledge or experience to testify as an expert witness regarding the medical cause of hepatitis C transmission at the Endoscopy Clinic of Southern Nevada," and that the defendants must have qualified, competent expert testimony given to a reasonable degree of medical probability for their alternative causation theory. 

(Photo:  http://photos.prnewswire.com/prnh/20110805/LA48404)

Plaintiff Anne Arnold was exposed to the virus hepatitis C when a contaminated jumbo 50mL infusion vial of the anesthesia medication Propofol was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada on July 13, 2007. 50mL infusion vials of Propofol are meant for long tern sedation of patients, not short outpatient procedures like colonoscopies. Arnold was later diagnosed as having contracted hepatitis C. The lawsuit filed by Mainor Eglet alleges design defect, breach of implied warranty for a particular purpose, failure to properly warn by sending a Dear Health Care Professional letter and duty to monitor. 

In the complaint filed in Clark County District Court by Mainor Eglet Law Firm attorneys Robert Eglet, Robert Adams and Artemus Ham on behalf of plaintiffs Anne Arnold and spouse James Arnold -- the defendants Teva Parenteral Medicines, Inc.; SICOR Inc. and Baxter Healthcare Corporation -- are each responsible in some manner for causing injury and damages to the plaintiffs.  

"There are two primary issues in the Arnold case: the multi-dosing of Propofol between patients from 50mL jumbo infusion vials not intended for short medical procedures like colonoscopies, and the labels on the vials of Propofol provided inadequate warnings about intended use. Teva and Baxter were responsible for providing 50mL infusion vials of Propofol to the Endoscopy centers because profit dictated the decision to do so. Teva and Baxter's attempt to place the blame exclusively on the health care professionals is a complete disregard for the lives of thousands of Nevadans and their families. Drug companies are not allowed to put profit over patient safety," says Robert Eglet.  


'/>"/>
SOURCE Mainor Eglet Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Sky One Medical Announces Conference Call to Discuss Second Quarter 2011 Results
2. China Nepstar Chain Drugstore to Report Second Quarter 2011 Financial Results on August 23
3. QIAGEN Completes Second U.S.Submission for Companion Diagnostic to Guide Treatment Decisions in Colorectal Cancer
4. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
6. HeartWare International Reports Second Quarter 2011 Revenues of $20.4 Million; 109% Increase From $9.8 Million in Second Quarter 2010
7. Cumberland Pharmaceuticals Reports Second Quarter 2011 Financial Results
8. Isis Reports Financial Results and Highlights for Second Quarter 2011
9. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
10. Nektar Therapeutics Reports Second Quarter 2011 Financial Results
11. Valeant Pharmaceuticals Reports 2011 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 2016 Vestagen Technical Textiles, Inc., a medical ... healthcare and other demanding applications, today announced it has ... replaces Dale Pfost , PhD, who was serving ... also joining Vestagen,s Board of Directors. ® ... barrier technologies that combines fluid repellent, antimicrobial and breathability ...
(Date:2/8/2016)... Ill. , Feb. 8, 2016  Astellas Pharma Inc. ... announced the promotion of James Robinson as president, ... company,s operations in North and South America ... Astellas Pharma US, representing the commercial organization in ... in 2013. Masao Yoshida , who is ...
(Date:2/8/2016)... , Feb. 8, 2016  CTI BioPharma Corp. ... Company received written communication from the U.S. Food and ... FDA has placed a partial clinical hold on the ... Drug ("IND") application for pacritinib. This clinical hold impacts ... the IND and will also affect planned clinical trials. ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. announced today ... the tools and information to lower the costs, and increase the impact of ... providing employee healthcare benefits by as much as 22%:, + Price and ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... eating disorder treatment helps to reduce the frequency and level of relapse. ... Phase: Re-Establishing Healthy Identity and Purpose,” will explore the critical tasks of the ...
(Date:2/5/2016)... ... 2016 , ... VeloReality President and co-founder Gary ... VR Indoor Trainer with multi-rider capability to an enthusiastic audience at the company's ... the weight of the unit, they also enhance the rider's experience with a ...
Breaking Medicine News(10 mins):